Australia markets open in 4 hours 39 minutes

TFF Pharmaceuticals, Inc. (TFFP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9500+0.0300 (+1.56%)
As of 03:19PM EDT. Market open.

TFF Pharmaceuticals, Inc.

1751 River Run
Suite 400
Fort Worth, TX 76107
United States
817 438 6168
https://tffpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees19

Key executives

NameTitlePayExercisedYear born
Dr. Harlan F. WeismanPresident, CEO & Director742.5kN/A1952
Mr. Kirk Allen ColemanCFO, Treasurer & Secretary409.94kN/A1974
Dr. Zamaneh Mikhak M.D.Chief Medical Officer545.38kN/A1964
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Corporate governance

TFF Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.